銀座アテナクリニック本院
Explore the institution's name, address and registered technologies as published, along with plan classifications, score components and sources.
The ranking reflects only the registration data published by Japan's Ministry of Health, Labour and Welfare; it does not represent treatment outcomes or quality of care. Scoring method →
Source: Ministry of Health, Labour and Welfare public directory of regenerative medicine providers MHLW e-Regenerative Medicine public register · Directory archive date I: 2026-07-19 / II: 2026-09-26 / III: 2026-05-18 · Internet Archive
02C2601024 +1Location
- Prefecture
- Tokyo
- Address
- 中央区銀座7-10-5オーブルミナス3F
Plan classification
- Class INot registered
- Class IINot registered
- Class IIIThe low-risk category under the law.
Certified committee for regenerative medicine
- 日本薬事法務学会認定再生医療等委員会
- 日本薬事法務学会再生医療等委員会
Public score
26.2/ 100
- A · Review level
- 10.0 / 30
- B · Technologies
- 12.6 / 35
- C · Coverage
- 3.6 / 25
- D · Class I / II technologies
- 0.0 / 10
The public score is calculated from public registration information and does not reflect quality of care. Scoring method →
Registered technologies (2)
NK and immune cells 2
| Registered technologies · Japanese original | Technology areas | Plan classification |
|---|---|---|
| GMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®) | NK and immune cells | Class III |
| 免疫アジュバントによる免疫機能向上を主たる目的とした全血採血による高品質Alpha-GalactosylceramideとCD1d抗原提示DCによる活性化NKT細胞標的治療(RIKEN-NKT®Ⅱ) | NK and immune cells | Class III |
Certified committee for regenerative medicine
- 日本薬事法務学会認定再生医療等委員会
- 日本薬事法務学会再生医療等委員会
Public document number
02C260102402C2601026
Plan classification · Certified committee for regenerative medicine · Public document number
| Registered technologies | Plan classification | Certified committee for regenerative medicine | Public document number |
|---|---|---|---|
| GMP準拠Alpha-GalactosylceramideとCD1d抗原提示自己樹状細胞を用いたNKT細胞標的治療(RIKEN-NKT®) | Class III | 日本薬事法務学会認定再生医療等委員会 | 02C2601024 |
| 免疫アジュバントによる免疫機能向上を主たる目的とした全血採血による高品質Alpha-GalactosylceramideとCD1d抗原提示DCによる活性化NKT細胞標的治療(RIKEN-NKT®Ⅱ) | Class III | 日本薬事法務学会再生医療等委員会 | 02C2601026 |
Other institutions in the same prefecture
- GINZA中央クリニックPublic score 26.2
- K.Clinic HIROOPublic score 26.2
- KAIKAクリニックPublic score 26.2
- M再生クリニックPublic score 26.2
- あたまと体のヘルスケア・クリニック神田Public score 26.2
- ソラリアクリニック東京Public score 26.2
- ホリスティッククリニック銀座Public score 26.2
- ようようインターナショナルクリニックPublic score 26.2